Boston Scientific branding over surgical device handling in sterile lab, reflecting medical device innovation and growth. Key Points Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance. Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition. A potential majo ...

Group 1 - Boston Scientific Corp (NYSE:BSX) is recognized as one of Goldman Sachs' top healthcare stocks, with TD Cowen stating that the stock's year-to-date decline seems excessive [1][3] - The company has shown a positive outlook for its pulsed-field ablation and Watchman products, with a reported revenue growth of 19.9% over the past 12 months, indicating strong operational momentum [3][4] - TD Cowen has reiterated a Buy rating on Boston Scientific with a price target of $100, following solid fourth-quarter and full-year 2025 earnings, where revenue rose 15.9% year over year and adjusted earnings per share reached $0.80, surpassing consensus estimates [4][5] Group 2 - Boston Scientific is a global leader in medical technology, specializing in the development, manufacturing, and marketing of less-invasive medical devices for various interventional specialties, including cardiology and urology [5]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted EPS for Q4 was $0.80, growing 15% year-over-year, exceeding guidance [19] - Full year 2025 adjusted EPS was $3.06, reflecting a 22% increase compared to 2024, marking the third consecutive year of 20%+ adjusted EPS growth [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved 8% organic growth in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% organically for the full year, with strong performance from the brain franchise [6] - Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth segments and expanding product offerings [24][25] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key areas [52][63] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to face challenges in the first half of 2026 due to product discontinuations but anticipates a stronger performance in the second half [46] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive future growth [63] Other Important Information - The company expects full-year 2026 adjusted gross margin to be in line with 2025, with a slight expansion in operating margin anticipated [21] - Free cash flow for 2025 was $3.659 billion, exceeding expectations, with a target of approximately $4.2 billion for 2026 [24] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that U.S. EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [34][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials on Watchman uptake, with robust growth continuing [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to be around 15%, with confidence in maintaining market leadership despite increased competition [44][51] Question: Diversification of growth drivers - Management emphasized ongoing investments in various business units, including Neuromodulation and Urology, to ensure consistent performance across the portfolio [60][62] Question: Confidence in long-term growth targets - Management reaffirmed confidence in achieving long-term revenue growth targets of 10%+, supported by strategic acquisitions and market leadership [86]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted earnings per share for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [19] - Full year 2025 adjusted earnings per share was $3.06, growing 22% versus 2024, also exceeding guidance [20] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [21] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% for the full year, with the brain franchise showing low double-digit growth [6] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Nalu Medical and Valencia Technologies, are aimed at enhancing the company's portfolio in neuromodulation and urology [24][25] - The company is focused on expanding its pain portfolio and enhancing operational efficiencies through new product launches and partnerships [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 10%-11% for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to maintain a strong market position despite competitive pressures, particularly in the EP segment [34][45] - Management highlighted the importance of upcoming clinical trial results, particularly for the Watchman product, which could significantly impact growth [81] Other Important Information - The company expects full-year free cash flow to be approximately $4.2 billion for 2026, with a target conversion rate of 70%-80% [24] - The adjusted tax rate for 2026 is forecasted to be around 12.5% [27] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [33][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [45] Question: Capacity issues in EP labs - Management acknowledged capacity constraints but emphasized ongoing efforts to build out ASCs and repurpose cath labs to alleviate wait times [72] Question: Confidence in long-term growth targets - Management remains confident in achieving 10%+ organic revenue growth through 2028, supported by strategic acquisitions and market leadership [86]

Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [18] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [19] - Adjusted EPS for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [18] - Full year 2025 adjusted EPS was $3.06, growing 22% versus 2024, also exceeding guidance [19] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [20] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [4] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [4] - Neuromodulation grew 10% in Q4 and delivered 8% organic growth for the full year, with strong performance from the brain franchise [5] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [6] - Watchman business grew 29% in Q4 and maintained strong double-digit growth for the full year [12] Market Data and Key Metrics Changes - U.S. operational growth was 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [2] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [3] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [2] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [3] - Strategic acquisitions, including Penumbra and Valencia Technologies, are aimed at entering high-growth markets and expanding product offerings [24][6] - The company is focused on maintaining a strong pipeline of innovative products and expanding its market share in key segments [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 10%-11% organic revenue growth for 2026, with adjusted EPS growth of 12%-14% [27] - The company expects to face challenges in the first half of 2026 due to product removals and market adjustments but anticipates stronger performance in the latter half [25][43] - Management highlighted the importance of ongoing investments in R&D and strategic M&A to drive long-term growth [61] Other Important Information - The company reported free cash flow of $3,659 million for the full year 2025, exceeding expectations [22] - The legal reserve was $242 million as of December 31, with $46 million already funded [24] - The company maintains a strong balance sheet with cash on hand of $1.965 billion and a gross debt leverage ratio of 1.9 times [23] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management reassured that Q4 results exceeded internal targets, with EP growing 35% and Watchman growing 29%, indicating strong market share gains [30][34] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [36][38] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [41][42] Question: Diversification of growth drivers - Management highlighted strong performance expected in Neuromod, Urology, and Endoscopy, with ongoing investments to ensure consistent growth across all business units [59][60]

Core Viewpoint - Boston Scientific Corporation (BSX) is a global medical device company with a market cap of $138.8 billion, focusing on innovative technologies across various medical specialties, including cardiovascular and gastrointestinal conditions [1] Financial Performance - BSX shares have underperformed the broader market, decreasing 8.3% over the past 52 weeks, while the S&P 500 Index gained 15% [2] - Year-to-date, BSX shares have declined 1.6%, compared to the S&P 500's 1.9% return [2] - The company's stock also lagged behind the State Street Health Care Select Sector SPDR ETF's 5.3% rise over the past year [3] Recent Developments - On October 22, 2025, BSX shares rose nearly 4% after reporting Q3 2025 adjusted EPS of $0.75 and revenue of $5.07 billion, exceeding expectations [4] - The company raised its 2025 adjusted EPS forecast to a range of $3.02 - $3.04 and guided Q4 adjusted EPS of $0.77 - $0.79, above consensus estimates [4] - Strong demand for heart devices, particularly a 23.1% increase in electrophysiology sales driven by the Watchman and Farapulse systems, contributed to investor optimism [4] Analyst Ratings and Forecasts - Analysts expect BSX's adjusted EPS to grow 21.1% year-over-year to $3.04 for the fiscal year ending December 2025 [5] - The company has a promising earnings surprise history, beating consensus estimates in the last four quarters [5] - Among 31 analysts covering BSX, the consensus rating is a "Strong Buy," with 26 "Strong Buy" ratings, three "Moderate Buys," and two "Holds" [5] Price Targets - Bernstein analyst Lee Hambright maintained a "Buy" rating on BSX with a price target of $130 [6] - The mean price target of $125.53 indicates a 33.8% premium to BSX's current price levels [6] - The highest price target of $140 suggests a potential upside of 49.3% [6]

Boston Scientific Conference Call Summary Company Overview - **Company**: Boston Scientific - **Analyst**: Robbie Marcus, MedTech Analyst at J.P. Morgan - **Key Executives Present**: Mike Mahoney (CEO), Jon Monson (CFO), Dr. Stein (Chief Medical Officer) Key Industry Insights Market Growth and Product Launches - Boston Scientific is committed to achieving **10%+ growth** over the next three years and **150 basis points of margin improvement** [2] - The company anticipates an increase in the weighted average market growth rate from **8% in 2025 to 9%** over the next three years [2] - The **Pulsed Field Ablation (PFA)** market is projected to grow at a minimum of **15%+** annually, with the overall market growth reaching **20%** in 2025 [4][10] Product Highlights - **Pulsed Field Ablation**: Recognized as a leading product in the medtech market, with significant market share and growth potential [4] - **FARAPOINT**: Recently approved for use in the U.S. and Europe, expected to enhance the portfolio for arrhythmias and expand into non-AF ablations [11][18] - **Watchman**: Holds a **91% market share** in left atrial appendage closure (LAAC), with potential for growth in concomitant procedures [28][30] Competitive Landscape - Boston Scientific's leadership in the PFA market is attributed to strong execution and a comprehensive product pipeline [6] - The company emphasizes the importance of having a complete toolset for electrophysiology (EP) procedures, which includes various catheter types and access solutions [11][19] Financial Performance and Projections Revenue and Market Position - The company is confident in its ability to meet investor day targets and has consistently delivered on commitments [26] - Anticipated growth in the **interventional oncology** and **vascular therapies** divisions, with ongoing trials and product launches expected to drive revenue [40][42] Pricing Strategy - Boston Scientific aims to maintain flat pricing, with expectations of slight declines in certain markets due to competitive pressures [64] - The company has improved its pricing strategy, targeting flat pricing after previously facing headwinds [61] Strategic Initiatives Innovation and R&D - Boston Scientific invests heavily in both internal and external innovation, with a focus on maintaining a strong pipeline and venture portfolio [56][57] - The company is committed to improving operational efficiency, with ongoing initiatives in AI and ERP systems to enhance productivity [62] Market Expansion - The company is optimistic about growth in **China**, projecting sustainable growth in the teens despite market challenges [66] - Boston Scientific is also exploring opportunities in the **ASC (Ambulatory Surgery Center)** market to increase patient volumes and lab capacity [14][15] Additional Insights Clinical Trials and Future Opportunities - The **AVANT GUARD trial** aims to establish catheter ablation as a first-line therapy for persistent atrial fibrillation, with results expected to influence future treatment protocols [21] - The company is exploring the use of its products in various clinical settings, including potential applications for ventricular tachycardia and redo ablations [18][19] Conclusion - Boston Scientific is well-positioned for continued growth with a robust product pipeline, strong market leadership, and a commitment to innovation and operational efficiency. The company is focused on leveraging its competitive advantages in the medtech space to drive future success.

Core Insights - Parnassus Investments reported that the S&P 500 Index increased by 8.12% in Q3 2025, driven by investor optimism regarding monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, and has a year-to-date return of 9.89% compared to the index's 14.83% [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) experienced a one-month return of -4.86% but gained 5.89% over the last 52 weeks, with a market capitalization of $142.952 billion as of December 22, 2025 [2] - The company reported consolidated revenue of $5.065 billion for Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] Investment Strategy - The Parnassus Core Equity Fund made strategic moves in the Health Care sector by trimming positions in Eli Lilly and Stryker to initiate a position in Boston Scientific Corporation, citing its first-mover advantage and robust clinical data as key growth drivers [3] - Management's focus on disciplined R&D and M&A has led to organic sales growth and margin expansion, positioning Boston Scientific for durable growth [3]

Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is highlighted as a top investment opportunity in the healthcare AI sector, with TD Cowen reaffirming a Buy rating and setting a price target of $115, naming it their "Best Idea for 2026" [1] Group 1: Growth Potential - TD Cowen describes Boston Scientific as "the most attractive growth story in the medical devices sector," supported by expectations of over 10% organic sales growth annually, 50 basis points of yearly operating margin expansion, and double-digit EPS growth [1][2] - Analysts anticipate that Boston Scientific will maintain double-digit organic revenue growth through 2026, despite facing tougher year-over-year comparisons [1] Group 2: Competitive Advantage - Boston Scientific's proven history of strong double-digit earnings growth justifies higher valuation multiples due to its "scarcity value," as few companies can match this reliable high growth [2] - Key products driving this growth include Farapulse for atrial fibrillation treatment and Watchman for stroke prevention [2] Group 3: Innovation and Market Strategy - At the 7th Annual Wolfe Research Healthcare Conference, Boston Scientific's management discussed the company's innovation pipeline and market expansion strategies, particularly in electrophysiology [3] - The Farapulse pulsed field ablation (PFA) system is projected to exceed 50% market penetration in the US by the end of 2025 [3] - Historical trials for the Watchman device were discussed, highlighting limitations from older device generations and post-procedure regimens [3] Group 4: Technological Integration - Boston Scientific develops medical devices across various fields, including cardiology, endoscopy, neuromodulation, and urology, utilizing machine learning, natural language processing, and computer vision to enhance medical imaging and patient management [4]

Financial Data and Key Metrics Changes - The electrophysiology (EP) business has experienced significant growth, with FARAPULSE driving growth at approximately twice the market rate since its introduction in the EU in 2021 [2][4] - The U.S. market penetration for FARAPULSE has quickly surpassed 50%, indicating strong adoption and market presence [4][5] Business Line Data and Key Metrics Changes - The FARAPULSE ecosystem, including FARAWAVE catheter and Opal mapping system, has been pivotal in driving success across global markets [2][3] - The Watchman franchise is projected to be a long-term growth engine for the company, with expectations of over 20% growth depending on the outcomes of OPTION and CHAMPION trials [14][17] Market Data and Key Metrics Changes - The global electrophysiology market is valued at $13 billion, with $9 billion attributed to atrial fibrillation (AF) and $4 billion to other indications [9] - The renal denervation market is being re-evaluated, with hypertension being a common condition affecting one in four adult Americans, presenting a significant opportunity for device-based therapies [38] Company Strategy and Development Direction - The company is focused on expanding its leadership in the electrophysiology market while exploring adjacent markets such as diabetes [9][10] - There is a strategic emphasis on category leadership across various medical technology segments, including interventional cardiology and structural heart [62][63] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the competitive landscape in cardiology, emphasizing the importance of understanding competition and focusing on their ecosystem of products [10][12] - The company is preparing for a shift of inpatient procedures to outpatient settings, aligning with CMS goals to enhance accessibility [47][48] Other Important Information - The company is investing in artificial intelligence to enhance product development and operational efficiency, with applications in imaging and electrophysiology [59][61] - The upcoming CHAMPION trial is expected to significantly expand the eligible patient population for the Watchman device, potentially tripling its total addressable market to $6 billion by 2030 [17][18] Q&A Session Summary Question: What is the growth outlook for the Watchman franchise? - The Watchman franchise is expected to grow over 20% long-term, contingent on positive outcomes from the OPTION and CHAMPION trials [14][17] Question: How does the company view the competitive landscape in electrophysiology? - The company recognizes the competitive nature of the market but believes it has a strong understanding of upcoming competition and is focused on its product ecosystem [10][12] Question: What is the timeline for the Seismic device and clinical data? - The Seismic device is currently enrolling in the Fracture ID study, with completion anticipated in Q1 2026 and a commercial launch expected in the first half of 2027 [30][31] Question: How does the company plan to address the access issues in renal denervation? - The company plans to focus on educating both physicians and patients about the therapy, which is crucial for market development [45][46] Question: What are the expectations for the CRM market? - The CRM market is currently the lowest growth area for the company, but a complete revamp of the CRM portfolio is underway, aiming for at or above market growth [50][52]